Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3b influenced by CD44 and RHAMM

Stem Cells

Volumn 31, Issue 10, 2013, Pages 2073-2083

  Shigeishi, Hideo ^a,b   Biddle, Adrian ^a   Gammon, Luke ^a   Emich, Helena ^a   Rodini, Camila O ^a   Gemenetzidis, Emilios ^a   Fazil, Bilal ^a   Sugiyama, Masaru ^b   Kamata, Nobuyuki ^b   MaCkenzie, Ian C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cancer stem cells; CD44; Glycogen synthase kinase 3b; Head and neck squamous cell carcinoma; Receptor for hyaluronan mediated motility

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN B; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; HYALURONIC ACID BINDING PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL FUNCTION; CELL GROWTH; CELL RENEWAL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PHENOTYPIC PLASTICITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION;

CANCER STEM CELLS; CD44; GLYCOGEN SYNTHASE KINASE 3Β; HEAD AND NECK SQUAMOUS CELL CARCINOMA; RECEPTOR FOR HYALURONAN-MEDIATED MOTILITY;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; EXTRACELLULAR MATRIX PROTEINS; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84886243809     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1418     Document Type: Article

References (47)

1. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
2. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
3. Al-Hajj M., Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
4. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65: 10946-10951.
5. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-10163.
6. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037.
7. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007;104: 973-978.
8. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
9. Harper LJ, Piper K, Common J et al. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007;36:594-603.
10. Patrawala L, Calhoun T, Schneider-Broussard R et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708.
11. Wang SJ, Wong G, de Heer AM et al. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009; 119:1518-1530.
12. Bourguignon LY, Wong G, Earle C et al. Hyaluronan-CD44v3 interaction with Oct4/Sox2/Nanog promotes miR-302 expression leading to self-renewal, clonal formation and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012;287:32800-32824.
13. Zoller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;211:254-267.
14. Turley EA, Noble PW, Bourguignon LY Signaling properties of hya-luronan receptors. J Biol Chem 2002;277:4589-4592.
15. Wang C, Entwistle J, Hou G et al. The characterization of a human RHAMM cDNA: Conservation of the hyaluronan-binding domains. Gene 1996;174:299-306.
16. Shigeishi H, Fujimoto S, Hiraoka M et al. Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas. Int J Oncol 2009;34:1565-1571.
17. Telmer PG, Tolg C, McCarthy JB et al. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? Commun Integr Biol 2011;4: 182-185.
18. Hamilton SR, Fard SF, Paiwand FF et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 2007;282: 16667-16680.
19. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells - An integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-749.
20. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-454.
21. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133: 704-715.
22. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138: 645-659.
23. Biddle A, Liang X, Gammon L et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011;71:5317-5326.
24. Chen YC, Chen YW, Hsu HS et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009;385:307-313.
25. Locke M, Heywood M, Fawell S et al. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res 2005;65: 8944-8950.
26. Dontu G, Wicha MS Survival of mammary stem cells in suspension culture: Implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:75-86.
27. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776.
28. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J 1998;329:209-223.
29. Pap M, Cooper GM Role of glycogen synthase kinase-3 in the phos-phatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 1998;273:19929-19932.
30. Mishra R. Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Mol Cancer 2010;9:14.
31. Higashikawa K, Yoneda S, Tobiume K et al. Snail-induced down-regulation of DeltaNp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res 2007;67:9207-9213.
32. Kudo Y, Kitajima S, Ogawa I et al. Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 2004;10:5455-5463.
33. Proby CM, Purdie KJ, Sexton CJ et al. Spontaneous keratinocyte cell lines representing early and advanced stages of malignant transformation of the epidermis. Exp Dermatol 2000;9:104-117.
34. Liang CC, Park AY, Guan JL In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2:329-333.
35. Rajarajan A, Stokes A, Bloor BK et al. CD44 expression in oro-pha-ryngeal carcinoma tissues and cell lines. Plos One 2012;7:e28776.
36. Ding Q, Xia W, Liu JC et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005;19:159-170.
37. Biddle A, Gammon L, Fazil B et al. CD44 staining of cancer stemlike cells is influenced by down regulation of CD44 variant isoforms in the population of cells that has undergone epithelial-to-mesenchy-mal transition. PLoS One 2013;8:e57314.
38. Liu S, Clouthier SG, Wicha MS Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 2012; 17:15-21.
39. Yan D, Avtanski D, Saxena NK et al. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent Pathways. J Biol Chem 2012;287:8598-8612.
40. Cross DA, Alessi DR, Cohen P et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378: 785-759.
41. Subramaniam V, Vincent IR, Gardner H et al. CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation. Exp Mol Pathol 2007;83:207-215.
42. Hardwick C, Hoare K, Owens R et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol 1992;117:1343-1350.
43. Brown RL, Reinke LM, Damerow MS et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelialmesenchymal transition and breast cancer progression. J Clin Invest 2011; 121:1064-1074.
44. Brabletz T. To differentiate or not - Routes towards metastasis. Nat Rev Cancer 2012;12:425-436.
45. Lopez-Novoa J.M., Nieto MA Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med 2009; 1:303-314.
46. Buijs JT, Henriquez NV, van Overveld PG et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007;67:8742-8751.
47. Yee DS, Tang Y, Li X et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010;9:162. Technology